NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GRIFOLS S A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.64 +0.31 (+1.27 %) (As of 02/17/2020 06:00 AM ET) Add Today's Range$24.31Now: $24.64▼$24.6550-Day Range$22.64MA: $23.56▼$24.7652-Week Range$17.57Now: $24.64▼$24.82Volume914,541 shsAverage VolumeN/AMarket CapitalizationN/AP/E Ratio27.38Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:GRFS Previous Symbol CUSIPN/A CIK1438569 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio27.38 Forward P/E Ratio20.71 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees21,230 Outstanding SharesN/AMarket CapN/A Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive GRFS News and Ratings via Email Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GRFS Rates by TradingView GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions What is GRIFOLS S A/S's stock symbol? GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS." How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S? GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Investors of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is a boost from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History. When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work? GRIFOLS S A/S's stock split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split. When is GRIFOLS S A/S's next earnings date? GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S. What price target have analysts set for GRFS? 5 Wall Street analysts have issued 1 year target prices for GRIFOLS S A/S's shares. Their forecasts range from $22.50 to $22.50. On average, they expect GRIFOLS S A/S's share price to reach $22.50 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for GRIFOLS S A/S. What is the consensus analysts' recommendation for GRIFOLS S A/S? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S. Has GRIFOLS S A/S been receiving favorable news coverage? News articles about GRFS stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a news impact score of 1.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for GRIFOLS S A/S. Are investors shorting GRIFOLS S A/S? GRIFOLS S A/S saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,550,000 shares, an increase of 97.7% from the January 15th total of 1,290,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.0% of the shares of the company are sold short. View GRIFOLS S A/S's Current Options Chain. What other stocks do shareholders of GRIFOLS S A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Teva Pharmaceutical Industries (TEVA), Nektar Therapeutics (NKTR), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Novartis (NVS), Pfizer (PFE), Southern Copper (SCCO) and Exxon Mobil (XOM). Who are GRIFOLS S A/S's key executives? GRIFOLS S A/S's management team includes the folowing people: Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs Who are GRIFOLS S A/S's major shareholders? GRIFOLS S A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FIL Ltd (1.78%), Credit Suisse AG (1.76%), Pictet Asset Management Ltd. (1.50%), Black Creek Investment Management Inc. (0.60%), UBS Asset Management Americas Inc. (0.44%) and First Trust Advisors LP (0.36%). Which institutional investors are selling GRIFOLS S A/S stock? GRFS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., First Trust Advisors LP, Envestnet Asset Management Inc., Renaissance Technologies LLC, UBS Group AG, CIBC Private Wealth Group LLC and Todd Asset Management LLC. Which institutional investors are buying GRIFOLS S A/S stock? GRFS stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Amia Capital LLP, Axiom International Investors LLC DE, UBS Asset Management Americas Inc., FIL Ltd, SG Americas Securities LLC, Marshall Wace LLP and Reilly Financial Advisors LLC. How do I buy shares of GRIFOLS S A/S? Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is GRIFOLS S A/S's stock price today? One share of GRFS stock can currently be purchased for approximately $24.64. MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 295 (Vote Outperform)Underperform Votes: 413 (Vote Underperform)Total Votes: 708MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What is Liquidity?
